HR Execs on the Move

Lundbeck

www.lundbeck.com

 
Lundbeck is a global pharmaceutical company highly committed to improving the quality of life of people living with psychiatric and neurological disorders. For this purpose, Lundbeck is engaged in the research, development, production, marketing and sale of pharmaceuticals across the world. The company`s products are targeted at disease areas such as depression, schizophrenia, Parkinson`s disease and Alzheimer`s disease. According to the World Health Organization, WHO, more than 700 million cases of psychiatric and neurological disorders are reported every year. These are serious and life-threatening diseases that affect the quality of life of the patients as well as of their relatives. ...
  • Number of Employees: 1K-5K
  • Annual Revenue: $100-250 Million
  • www.lundbeck.com
  • Six Parkway North Suite 400
    Deerfield, IL USA 60015
  • Phone: 847.282.1000

Executives

Name Title Contact Details
Jennifer Wheeler
Team Leader Project and CMO Profile
Markus Kede
VP, Finance, Strategy and Business Planning Profile
Joerg Hornstein
CFO Profile
Helen Carberry
Head of Human Resources and Development Profile

Similar Companies

Surface Ophthalmics

Surface Ophthalmics, Inc. is a pharmaceutical company focused on development and commercialization of innovative therapeutics for ocular diseases.

4 dry skin natural products

4 dry skin natural products is a Nashville, KY-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Norwich Pharmaceuticals

Norwich Pharmaceuticals, Inc. is a Norwich, NY-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Corcept Therapeutics

Corcept Therapeutics Incorporated, a pharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of metabolic, oncologic, and psychiatric disorders in the United States. The company focuses on disorders that are associated with a steroid hormone called cortisol. It offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing’s syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. The company is also developing Korlym’s active ingredient, which is in a Phase 1/2 trial in combination with the chemotherapy drug eribulin (Halaven) to treat patients with GR-positive triple-negative breast cancer, a form of cancer with a particularly poor prognosis; and CORT 125134, a proprietary, selective GR antagonist that is in a Phase 1 clinical study to assess its safety, tolerability, and pharmacokinetics in healthy human volunteers. In addition, it discovers and develops three series of novel selective GR-II antagonists. The company has research and development agreements with Argenta Discovery Limited and Sygnature Discovery Limited. Corcept Therapeutics Incorporated was founded in 1998 and is headquartered in Menlo Park, California.

Diamatrix

Founded in 1993, Diamatrix helped usher in a new era of cataract surgery with its revolutionary Trapezoid diamond blade. Designed in conjunction with Clear Cornea pioneer, Dr. Charles H. Williamson, M.D. of the Williamson Eye Center in Baton Rouge, thi...